Scott Gottlieb, who served early on in Trump's first term, is now warning senators about the impact Kennedy could have on ...

Scott Gottlieb, who served as commissioner of the Food and Drug Administration (FDA) during President-elect Trump’s first ...

Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

The past couple of years have been terrific for stocks, with the benchmark S&P 500 index up a whopping 57.1% since the end of ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Many billionaires who definitely don't need income still have dividend stocks in their portfolios. Which dividend stocks ...